Retrospective study assessed efficacy of IL-1i, IL-6i, TNFαi, or JAKi therapy for VEXAS among 52 patients seen through Aug 2024.
IL-6i and JAKi therapies demonstrated limited, unsustained efficacy, while IL-1i and TNFαi therapies were not efficacious
ACROR
https://t.co/nGdKBtAzbg